https://www.selleckchem.com/products/cb-5083.html
61 [95% confidence interval 1.17,2.22]; p=0.004) and decrease in asthma control (hazard ratio 1.52 [1.13,2.02]; p=0.005), and higher blood eosinophil counts at Week 52 (270 versus 40 cells·µL-1; ratio [stopping versus continuing] 6.19 [4.89, 7.83]; p less then 0.001). Differences in efficacy outcomes between groups were observed when assessed from Week 12 (16 weeks after last mepolizumab dose). Exacerbations requiring hospitalisation/emergency department visit were rare. Adverse events in patients continuing mepolizumab were consistent
Like
Comment
Share
